Press Releases
Company News
View Summary Data From Phase 3 AFFIRM Trial of MDV3100 in Advanced Prostate Cancer to Be Highlighted in Late-Breaking Presentation at ASCO GU
Jan 9, 2012
PDF 10.1 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Dec 26, 2011
PDF 7.4 KB Add to Briefcase
View Summary Medivation Announces Participation at Three Upcoming Investor Conferences
Nov 23, 2011
PDF 7.8 KB Add to Briefcase
View Summary Medivation Names Sarah Noonberg Vice President of Clinical Development
Nov 17, 2011
PDF 7.8 KB Add to Briefcase
View Summary Medivation Reports Third Quarter 2011 Financial Results and Provides Corporate Update
Nov 9, 2011
PDF 22.0 KB Add to Briefcase
View Summary Medivation and Astellas Announce Positive Survival Data From Interim Analysis of Phase 3 AFFIRM Trial of MDV3100 in Men With Advanced Prostate Cancer
Nov 3, 2011
PDF 15.5 KB Add to Briefcase
View Summary Medivation Announces Third Quarter Financial Results Teleconference and Webcast on November 9, 2011
Nov 2, 2011
PDF 7.8 KB Add to Briefcase
View Summary Medivation Announces Participation at Two Upcoming Investor Conferences
Sep 23, 2011
PDF 8.0 KB Add to Briefcase
View Summary Medivation Names Cheryl Cohen Chief Commercial Officer
Sep 8, 2011
PDF 11.3 KB Add to Briefcase
View Summary Medivation Announces Participation at Two Upcoming Investor Conferences
Sep 6, 2011
PDF 8.1 KB Add to Briefcase
View Summary Medivation Reports Second Quarter 2011 Financial Results and Provides Corporate Update
Aug 9, 2011
PDF 21.4 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Preclinical Study Results Showing MDV3100 Blocks Breast Cancer Cell Growth
Aug 4, 2011
PDF 13.9 KB Add to Briefcase
View Summary Medivation Announces Second Quarter Financial Results Teleconference and Webcast on August 9, 2011
Aug 2, 2011
PDF 7.6 KB Add to Briefcase
View Summary Medivation Names Stewart Hallett Vice President of Clinical Operations
Jul 13, 2011
PDF 7.8 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Study Results Confirming Clinical Effects and Tolerability of MDV3100 in Advanced Prostate Cancer
Jun 4, 2011
PDF 13.1 KB Add to Briefcase
View Summary Medivation Announces Webcast of MDV3100 Investor Briefing at ASCO and Corporate Presentation at Jefferies Global Healthcare Conference
May 26, 2011
PDF 8.3 KB Add to Briefcase
View Summary Medivation and Astellas Announce Upcoming Presentation of MDV3100 Data at the American Society of Clinical Oncology Annual Meeting
May 19, 2011
PDF 10.9 KB Add to Briefcase
View Summary Medivation and Astellas Announce Upcoming Presentation of Long-Term Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
May 12, 2011
PDF 11.0 KB Add to Briefcase
View Summary Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients
May 9, 2011
PDF 13.9 KB Add to Briefcase
View Summary Medivation Reports First Quarter 2011 Financial Results and Provides Corporate Update
May 6, 2011
PDF 18.8 KB Add to Briefcase
Showing 81-100 of 290 Page: 1 2 3 4 5 6 7 8 9 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top